Introduction
Angiogenesis, defined as the formation of new capillaries from pre-existing ones, has a key role in growth and development of blood vessels, as well as in wound healing. Nonetheless, angiogenesis is also fundamental in pathological processes, such as cancer, in which the development of new blood vessels is critical for tumor growth as well metastasis. Tumor angiogenesis is mediated by the secretion of a large number of growth factors by tumor cells. These growth factors in turn stimulate endothelial cells (ECs) within the tumor to sprout, proliferate, migrate and finally differentiate into new blood vessels (Folkman, 2003; Carmeliet, 2005) . Endothelial cells were previously considered to be genetically stable when compared with tumor cells and therefore, were an ideal therapeutic target in the development of anti-angiogenic treatments. However, their stability has been questioned with several studies showing that tumor-derived EC (TEC) differ significantly from their normal counterparts at genetic and functional levels (St Croix et al., 2000; Hida et al., 2004; Bussolati et al., 2011) . Gene expression profiles obtained using microarrays and quantitative PCR revealed that tumor vasculature express unique markers that distinguish them from normal EC (St Croix et al., 2000; Bussolati et al., 2003; Bhati et al., 2008) . Furthermore, TEC from human melanoma, liposarcoma and breast carcinoma are resistant to apoptosis; in particular those from breast (BTEC) and renal (RTEC) carcinomas exhibit enhanced angiogenic properties and display an immature/embryonic phenotype (Bussolati et al., 2003; Grange et al., 2006) . The molecular mechanisms that are involved in promoting tumor growth and metastasis are still not well understood. Thus, studies focused directly on understanding the regulation of TEC function may provide useful information for development of TEC-based therapies.
Intracellular calcium (Ca 2 þ i ) signaling is a highly conserved and ubiquitous mechanism that controls various processes including cell survival, proliferation, motility, apoptosis and differentiation. Importantly, Ca 2 þ i signaling is critically involved in the regulation of angiogenesis (Patton et al., 2003; Munaron and Fiorio Pla, 2009; Prevarskaya et al., 2010) . We recently showed that arachidonic acid (AA), a lipid second messenger released by different pro-angiogenic factors (such as basic fibroblast growth factor and vascular endothelial growth factor), is actively involved in the early steps of the angiogenic process in vitro and mediates its effects by activating Ca 2 þ entry via Ca 2 þ -permeable plasma membrane channels. Carboxyamidotriazole, an inhibitor of Ca 2 þ entry and angiogenesis, has been shown to significantly and specifically decrease AA-induced tubulogenesis and Ca 2 þ entry in BTEC (Fiorio Pla et al., 2008) . However, the molecular nature of the plasma membrane channel(s) mediating such Ca 2 þ entry in BTEC is still unknown. The discovery of transient receptor potential (TRP) superfamily of channels provided putative candidates for non-voltagegated Ca 2 þ entry mechanisms, including Ca 2 þ entry channels induced by store depletion, mechanical stretch or second messengers such as inositol 1,4,5-trisphosphate or AA (Nilius et al., 2007; Birnbaumer, 2009) . Several TRP channels have been identified in a variety of ECs, for example, TRPC1, TRPC4, TRPC6, TRPV1 and TRPV4 (Kwan et al., 2007; Everaerts et al., 2010) . These channels appear to be differentially expressed in different types of ECs and show varying contributions to agonist-induced or mechanical stretchinduced Ca 2 þ entry (Meves, 2008; Everaerts et al., 2010) . In particular, TRPV4 (also called OTRPC4, TRP12 and VR-OAC) was shown to be distributed in a broad range of tissues including vascular endothelium, trachea, kidney, liver, heart, lung, testis, brain and ears. Although TRPV4 was initially described as being mainly activated by hypotonicity, it is now well known that it can be activated by mechanical stresses (for example, membrane stretch), chemical stimuli such as phorbol ester derivates (for example, 4a-Phorbol 12, 13-didecanoate (4aPDD), a specific agonist for TRPV4) or endogenous stimuli such as AA and its metabolites (Gao et al., 2003; Liedtke and Kim, 2005; Mutai et al., 2005) and has been shown to be expressed and functional in vascular endothelium. TRPV4 has been implicated in the regulation of vascular tone in large arteries (Hartmannsgruber et al., 2007) and is critical in mediating the shear-stress responses of microvessels and subsequent reorientation of ECs (Thodeti et al., 2009) . We have previously shown that AA-mediated Ca 2 þ entry is critical in the early events associated with TEC angiogenesis. AA directly or indirectly (via metabolites) activates several different calcium channels, including TRP channels from the TRPV and TRPM subfamilies. Of these TRPV4 has been proposed to be directly activated by epoxyeicosatrienoic acids, which are AA metabolites (Watanabe et al., 2003; Meves, 2008; Everaerts et al., 2010) . In the present study we have elucidated the Ca 2 þ channel targeted by AA that is involved in migration of TEC.
Herein, we report that the expression of endogenous TRPV4 is significantly higher in BTEC compared with 'normal' ECs (HMVEC). TRPV4 has a key role in mediating Ca 2 þ entry in BTEC as loss of TRPV4 expression resulted in decreased Ca 2 þ i responses to 4aPDD and complete inhibitions of AA-induced migration of BTEC. Finally, AA induced actin remodeling and increased surface expression of TRPV4 in BTEC. The latter was strongly displayed by migrating cells. Thus, our findings reveal that AA regulates angiogenesis by inducing remodeling of the cytoskeleton and stimulating TRPV4 channel activity, both of which are critical for TEC migration.
Results

Tumor-derived endothelial cells display high expression and function of TRPV4
BTECs were used in the present study as these cells represent a very good model to study tumor vascularization properties compared with normal tissue vascularization . Previous studies reported that migration of BTEC is greater than that of normal ECs . This is further demonstrated in Figure 1a using the wound-healing assay. BTEC displayed a higher migration rate as compared with normal human microvascular ECs isolated from derma (HMVEC-d) both in serum-free conditions and in endothelial basal medium (EBM) medium (both cell types displayed higher migration in the latter). Note that although HMVEC showed minimal migration in serum-free medium, BTEC displayed higher spontaneous migration. It should be noted that the total absence of serum was not optimal for the culture of HMVEC-d and therefore, subsequent experiments were conducted using in 2% fetal bovine serum as basal condition. As Ca 2 þ entry plays a critical role in EC migration, we examined whether BTEC and HMVEC were different in this aspect. Based on the reported role for AA in angiogenesis, we examined AA-induced Ca 2 þ mobilization in both cell types. Although AA induced an increase in intracellular Ca 2 þ concentration ([Ca 2 þ ] i ) in both cell types, the increase in BTEC was significantly more than in the normal cells (Figures 1bi and biii) . We have previously demonstrated that this [Ca 2 þ ] i increase is completely abolished in Ca 2 þ -free medium, suggesting that a major portion of it was due to extracellular Ca 2 þ entry (Fiorio Pla and Munaron, 2001; Fiorio Pla et al., 2008) . To determine whether TRPV4 mediates this Ca 2 þ entry, the TRPV4-specific agonist 4aPDD was used. As seen with AA, BTEC also demonstrated higher [Ca 2 þ ] i elevation than normal cells following 4aPDD stimulation (Figures 1bii  and biii) . Thus, both AA-and 4aPDD-induced Ca 2 þ responses were higher in BTEC compared with HMVEC.
TRPV4-mediated tumor derived endothelial cell migration A Fiorio Pla et al Endogenous TRPV4 expression has been reported in different types of ECs (both primary cells as well as cell lines) (Everaerts et al., 2010) . As shown in Figure 1c , the expression of endogenous TRPV4 was markedly higher in BTEC compared with HMVEC-d or ECs isolated from cardiac microvasculature (HMVEC-c). To assess whether increased endogenous TRPV4 expression was a common feature of TEC, protein expression in RTEC was compared with normal kidney glomerular EC (GEC).
Expression of endogenous TRPV4 was also higher in RTEC compared with 'normal' GEC ( Figure 1c Figure S1D (transfection with shTRPV4 for 72 h induced 450% knockdown of TRPV4 expression). In aggregate, the data in Figure 1 demonstrate that the expression and function of endogenous TRPV4 are significantly increased in TEC when compared with normal ECs.
TRPV4 activation is involved in AA-mediated tumorderived endothelial cell migration We then evaluated the role of TRPV4 in mediating EC migration using its specific agonist, 4aPDD. At each time point measured, BTEC consistently had a higher basal (that is, in 2% fetal bovine serum alone, CNTRLÀ) as well as serum-stimulated (EBM, CNTRL þ ) rate of cell migration than HMVEC-d (Figure 2 ). Further, when stimulated with 10 mM 4aPDD, BTEC migrated at a significantly faster rate than unstimulated cells. Notably, 4aPDD did not have any stimulatory effect on the migration rate of HMVEC-d (Figures 2a and b) . We have previously shown that AAinduced Ca 2 þ entry promotes the organization of BTEC into vessel-like structures in vitro, a phenomenon that is partly dependent on cell migration (Fiorio Pla et al., 2008) . HMVEC migration, on the other hand, was not effected by AA (Fiorio Pla et al., 2010) . Thus, woundhealing assays were conducted with BTEC to further TRPV4-mediated tumor derived endothelial cell migration A Fiorio Pla et al confirm the role of AA on EC migration. After incubating the cells with AA (5 mM) for at least 4 h, a significant increase in the migration rates of EC was observed ( Figure 3 ). Inhibiting TRPV4 channel activity using ruthenium red (1 mM), a pan-TRPV channel antagonist shown to block TRPV4 (Watanabe et al., 2002; Gao et al., 2003) , completely abolished AAinduced B-TEC migration (Figures 3a and bi) . Similarly, knocking down TRPV4 expression also completely abolished the pro-migratory effect of 5 mM AA and 10 mM 4aPDD on BTEC transfected with shTRPV4 (c.f. cells transfected with an empty short hairpin RNA (shRNA) vector) (Figures 3a and bii). These data suggest that TRPV4-mediated Ca 2 þ entry is required for AAinduced BTEC migration.
To further demonstrate TRPV4 involvement in EC migration, we analyzed TRPV4-mediated Ca 2 þ signaling in migrating versus non-migrating cells. 4aPDD-induced Ca 2 þ responses were compared in confluent (non-migrating) and migrating BTEC (the latter line the wound in a wound-healing assay) (Figure 4) . Importantly, the migrating cells showed significantly higher 4aPDD-induced Ca 2 þ responses on average when compared with confluent, non-migrating cells (n ¼ 13 experiments; Po0.05). Together these data demonstrate that TRPV4 has an important role in the migration of BTEC and potentially in tumor progression and metastasis. As TRPV4 function has been shown to depend on an intact cytoskeleton (Liu et al., 2006; Becker et al., 2009) , we hypothesized that the AA-induced synchronization of Ca 2 þ responses in BTEC maybe be caused by changes in the actin cytoskeleton. Thus, we examined the effect of actin depolymerization on TRPV4-mediated Ca (ii) 5 mM AA and 10 mM 4aPDD were not able to exert any migratory effect in shTRPV4-transfected BTEC. CNTRL: BTEC transfected with empty shRNA vector in DMEM 0% FCS; shTRPV4: BTEC transfected with shTRPV4 vector in DMEM 0% FCS; 4aPDD: BTEC transfected with empty shRNA vector in DMEM 0% FCS and stimulated with 10 mM 4aPDD; 4aPDD/shTRPV4: BTEC transfected with shTRPV4 vector in DMEM 0% FCS and stimulated with 10 mM 4aPDD; AA: BTEC transfected without vector in DMEM 0% FCS and stimulated with 5 mM AA; AA/shTRPV4: BTEC transfected with shTRPV4 vector in DMEM 0% FCS and stimulated with 5 mM AA; *, ** and y represent significant differences relative to CNTRL, AA and 4aPDD, respectively. Po0.05 (Wilcoxon test). Data are expressed as the mean value. A full colour version of this figure is available at the Oncogene journal online.
TRPV4-mediated tumor derived endothelial cell migration
A Fiorio Pla et al prevented the AA-induced synchronization of 4aPDD-induced Ca 2 þ responses in BTEC (Figure 5aiii ) with a corresponding increase in the range of latency distribution from 0 to 342 s with a mean value of 109.5 s and a median value of 90 s (very similar to the range obtained with 4aPDD stimulation alone; Figures 5b and c) . These novel data suggest that AA synchronizes TRPV4-mediated Ca 2 þ responses in BTEC likely by inducing actin remodeling.
Remodeling of the actin cytoskeleton increased endogenous TRPV4 expression at the plasma membrane To provide further evidence for the role of actin remodeling in AA-induced synchronization of TRPV4-mediated Ca 2 þ responses in BTEC, F-actin stress fibers were detected using phalloidin in BTEC expressing TRPV4-GFP. In untreated control cells, the network of actin stress fibers could be clearly detected in cells immobilized on a substrate (that is, gelatin) through focal adhesion formation (Figure 6Ai , left panels). Preincubation with 5 mM AA (10 min at 37 1C) induced remodeling of the actin cytoskeleton, resulting in partial disappearance of stress fibers and a concentration of actin in the cell periphery ( Figure 6Ai , right panels). This is in agreement with the pro-migratory role of AA as actin remodeling and partial rearrangement of stress fibers in cortical actin are required for cell migration. Using a plot profile traced along the major cell axis, the fluorescence signal for phalloidin was diffusely distributed in untreated control cells (Figure 6Aii , left graph). However, in cells pre-incubated with AA, the actin/ phalloidin signal was mostly localized in the cell periphery ( Figure 6Aii Figure S3) . Moreover, TRPV4 is not recruited to the plasma membrane of BTEC when the actin cytoskeleton is disrupted by cytochalasin D treatment per se (data not shown).
Pre-incubating BTEC with AA markedly increased the amount of TRPV4-GFP in the plasma membrane (Figure 6Bi , compare left and right panels). Figures 6Bii and Biii show the quantification of TRPV4-GFP in the plasma membrane region. The fluorescence intensity of TRPV4-GFP was traced along the axis of the cells using a plot profile. The green fluorescence protein (GFP) fluorescence signal was diffusely distributed throughout the cytoplasm in untreated control cells (Figures 6Bi and Bii; left panel and graph) . Following AA treatment, TRPV4-GFP was predominantly localized in the cell periphery as indicated by a higher fluorescence signal at both ends of the plot profile (Figure 6Bii ; left panel and graph). There was a clear and significant decrease of TRPV4-GFP fluorescence signal inside the cell, indicating that TRPV4-GFP was trafficked from the cytoplasm to the plasma membrane following AA stimulation (Figure 6Biii ). More importantly, there was clear colocalization of TRPV4-GFP with the actin/phalloidin fluorescent signal in BTEC ( Figure 6C , panels c-d and g-h). In resting, unstimulated cells, actin and TRPV4-GFP were diffusely localized in the cytoplasm Figure 6C, panels a and b) . Following AA treatment, TRPV4-GFP was trafficked on the plasma membrane region where it strongly colocalized with the cortical actin ( Figure 6C , panels e and f). Furthermore, surface biotinylation assays were performed in control and AA-treated BTEC. There was a significant increase in the surface expression of TRPV4 following AA treatment, compared with untreated control cells (Figure 7) . Together these findings demonstrate that, in addition to possible direct effects on TRPV4 channel activity, AA also increases the expression of TRPV4 channels in the plasma membrane by inducing remodeling of the actin cytoskeleton. The net result is an overall increase in active TRPV4 channels.
Discussion
Among the second messengers released upon stimulation of ECs with pro-angiogenic factors (such as basic fibroblast growth factor or vascular endothelial growth factor), the fatty acid AA and its metabolites promote the generation of Ca 2 þ i signals that are required for cell proliferation and migration and neo-angiogenesis We had previously shown that AA plays a key role in the formation of 'capillary-like structure' by tumorderived endothelial cells, BTEC (Fiorio Pla et al., 2008) .
In the present paper, we studied the molecular mechanism involved in AA-mediated pro-angiogenic effect and report for the first time that the non-selective cation channel, TRPV4, has an important role in mediating AA-induced cell migration and Ca 2 þ entry in TEC. Although several studies have demonstrated the importance of agonist-stimulated Ca 2 þ i signaling in the angiogenic process, very little is known about the molecular nature of the channels involved in mediating these responses. Recent evidence suggests a role for TRPC channels in vascular endothelial growth factorinduced Ca 2 þ responses and vascular permeability (Pocock et al., 2004) . TRPC6 has been shown to be a critical component of the channels mediating cation entry in response to vascular endothelial growth factor and 1-oleoyl-2-acetyl-sn-glycerol (OAG) in HMVEC (Hamdollah Zadeh et al., 2008) . Yu et al. (2010) reported that knockdown of TRPC1 caused severe angiogenic defects in intersegmental vessel sprouting of zebrafish, indicating that TRPC1 is required for angiogenesis in vivo. We proposed that the TRPV4 channel is a good candidate to mediate BTEC migration as the channel is activated in responses to changes in cell morphology, such as during cell swelling and shear stress. TRPV4 is also activated by endogenous compounds such as AA and its metabolites (for example, epoxyeicosatrienoic acids), which are important inflammatory messengers that may mediate migration of ECs toward sites of inflammation (Everaerts et al., 2010) . Furthermore, TRPV4 is widely expressed in the vascular endothelium in which it has been shown to function as a sensor for shear stress. The channel acts as a mechanosensor activated by mechanical stretching of ECs sensing the fluid shear stress that also regulates cell reorientation, whereas in larger arteries it functions as a key factor in shear stress-induced vasodilation (Hartmannsgruber et al., 2007; Thodeti et al., 2009) . Both shear stress and agonist-activation of TRPV4 stimulate proliferation of ECs and trigger collateral growth after arterial occlusion (Troidl et al., 2009) . On the other hand, the possible role of TRPV4 in cell migration has only been recently reported. Although TRPV1 had a predominant role in regulating migration of hepatoblastoma HepG2 cells, activation of TRPV4 channels resulted in increased lamellopodial dynamics that was reflected as a rise in the cell velocity (Waning et al., 2007) . In addition, Thodeti et al. (2009) had previously demonstrated that TRPV4 is a mechanosensor activated by mechanical stretching of ECs and regulates cell reorientation, a key element in the directional migration and oriented sprouting that drive angiogenesis.
Data from the present study show that TRPV4 has a central role in the regulation of BTEC migration. We report that both expression of TRPV4 and 4aPDD-mediated Ca 2 þ entry is increased in BTEC when compared with normal microvascular ECs. In this regard, it is interesting to note that increased endogenous TRPV4 expression is not restricted to BTECs and is also found in ECs derived from renal carcinomas. The pro-migratory effect of TRPV4 stimulation, by either 4aPDD or AA, on BTEC represents a direct link between TRPV4 and AA-mediated cell migration. Moreover, we demonstrate a clear 'positional effect' of TRPV4-mediated [Ca 2 þ ] i signaling in migrating versus non-migrating cells. The data are in accordance with our previous report that AA-mediated Ca 2 þ responses are involved in early stages of capillary-like structure organization of BTEC (Fiorio Pla et al., 2008) . Although the molecular mechanism responsible for organizing the capillary structure is not yet known, we propose that migrating Figure 7 Increased surface expression of TRPV4 following treatment with arachidonic acid. Cells were serum-starved for 2 h and then treated with AA for 10 min at 37 1C. As control, cells were only serum-starved. Following stimulation, cells were biotinylated and then harvested. Lysates were immunoprecipitated using neutravidin beads and TRPV4 was detected in western blot using the anti-TRPV4 antibody. The right panel of the blot shows the input levels, whereas the left panel shows TRPV4 detection in untreated control (CNTRL) and AA-treated (AA) cells. Band intensities were quantified and the histogram shows the average intensity values (mean±s.e.m.) for TRPV4 bands detected in control and AA-treated cells in 4 different immunoprecipitation experiments. The intensity value for control cells was set to 100% and the value for AA-treated cells was expressed relative to control cells. Statistical analysis was conducted using the Student's t-test and showed a significant increase in TRPV4 band intensity with AA treatment (*, Po0.03).
TRPV4-mediated tumor derived endothelial cell migration
A Fiorio Pla et al cells at the leading edges have higher Ca 2 þ 'responsiveness' and that could be, at least in part, due to AAinduced actin remodeling and a consequent increase in the trafficking of TRPV4 to the plasma membrane. As a result, there are more TRPV4 channels in the surface membrane of these cells and Ca 2 þ entry via these channels drives the migration of BTEC.
Previous studies have shown that AA metabolites affect actin dynamics by inducing an increase in actin polymerization (Peppelenbosch et al., 1995a, b; Moes et al., 2010) . AA and its metabolites activate signaling pathways that lead to the activation of GTPases such as Rac and Rho, ultimately resulting in actin remodeling (Peppelenbosch et al., 1995a; Shin et al., 1999) . In some studies, AA and some of its metabolites have been shown to bind directly to and regulate the activity of specific GTPase-activating proteins, which are in turn regulators of small GTPases (Tsai et al., 1989; Roberts et al., 2003) . Involvement of the cytoskeleton in regulation of TRPV4 channels has been previously reported. TRPV4 colocalized with actin in the keratinocyte-derived permanent cell line and this interaction was important for activation of TRPV4 by hypotonic cell swelling (Becker et al., 2005) . Similar results were obtained with human submandibular gland cells in which inhibition of actin remodeling impaired the hypotonic stress-induced trafficking of TRPV4 to the plasma membrane (Liu et al., 2006) . It was also shown that MAP-7 may mediate the interaction between TRPV4 and the actin cytoskeleton as TRPV4 interacts with MAP-7 via its C terminus and this interaction facilitates the expression of TRPV4 on the cell surface (Suzuki et al., 2003) . In addition, another recent study reported a direct interaction of TRPV4 with the actin cytoskeleton (Goswami et al., 2010) . It is also interesting to note that TRPV4, like TRPV1 and TRPV2, translocates to the plasma membrane in response to the agonist stimulation in cultured cells. Thus, regulated trafficking appears to be a common mechanism underlying the activation of TRPV channels by specific cellular stimulus/signals (Boels et al., 2001; MorenillaPalao et al., 2004; Van Buren et al., 2005; Liu et al., 2006) . In this regard, Ma et al. (2010) recently showed that TRPV4-TRPC1 heteromeric channel trafficking to the plasma membrane is enhanced by Ca 2 þ store depletion in human umbilical vein ECs. It would be interesting to elucidate the contribution of TRPC1 in BTEC as in addition to TRPV4, these cells also express TRPC1 (data not shown). It is also important to note that our data do not exclude a role for AA metabolites, as has been reported for epoxyeicosatrienoic acid (Watanabe et al., 2003) , in direct activation of TRPV4 in addition to increasing AA-mediated channel activity due to remodeling of the actin cytoskeleton and plasma membrane recruitment of the channel. Presently we have not clarified the exact AA metabolites involved in TRPV4 activation and actin remodeling. Nevertheless, the data demonstrate that TRPV4 surface expression is dependent on AA-induced actin remodeling, not vice versa. Once inserted the channel could be activated by epoxyeicosatrienoic acid or other AA metabolites.
In conclusion, the findings presented above demonstrate a role for TRPV4 in mediating the migration of TEC, which is one of the key processes involved in the neovascularization of tumors. Furthermore, AA-induced TRPV4 activation and cell migration is dependent on AA-induced remodeling of the actin cytoskeleton. Our data show that this cytoskeletal change facilitates TRPV4 trafficking to the plasma membrane in which it is activated.
Together our study reveals that TRPV4 channel is a potentially critical therapeutic target for the development of novel anti-angiogenic treatment strategies for breast tumors.
Materials and methods
Cell culture, transfection and plasmid construction Tumor-derived ECs were obtained from breast lobularinfiltrating carcinoma (BTEC) or from specimens of RTEC. Endothelial cells were isolated, using anti-CD105 antibody coupled to magnetic beads, by magnetic cell sorting using the MACS system (Miltenyi Biotec, Auburn, CA, USA) and grown in complete EBM medium (Lonza, East Rutherford, NJ, USA) supplemented with 10% fetal calf serum (FCS) (Lonza), 50 mg/ml gentamycin (Lonza) and 2 mM glutamine (Lonza) as previously described Grange et al., 2006) . Cells were used at passages 3-15. Primary microvascular EC lines obtained from GEC were prepared as previously described (Collino et al., 2008) . Briefly, human glomeruli were purified from specimens of normal renal tissue obtained for polar carcinomas by passages on sequential meshes, digested by trypsin (0.1%, 30 min at 37 1C), and plated onto gelatin in complete EBM medium. After 1 week, cells were detached and ECs were purified by using an anti-CD31 antibody coupled to magnetic beads by magnetic cell sorting using the MACS system (Miltenyi Biotec). To confirm their identity, BTEC, RTEC and GEC were characterized by cell morphology, expression of a panel of endothelial antigens (for example, CD105, CD31, Muc-18 (CD146), CD44 and VEGFR2 (KDR)), positive staining for the von Willebrand factor antigen and negative staining for cytokeratin and desmin . Adult human dermal microvascular ECs (HMVEC-d) and adult human cardiac microvascular ECs (HMVEC-c) were purchased from Lonza and grown in EGM2-MV medium (Lonza). Cells were used at passages 3-10.
BTEC and HMVEC cells were transfected using the Amaxa Basic Nucleofector Kit for mammalian ECs according to the instructions of the manufacturer using the M-003 program for B-TEC or S-005 for HMVEC-d (Lonza). Overall, 1 Â 10 6 B-TEC or 0.5 Â 10 6 HMVEC-d cells were transfected with 3 mg shTRPV4 or 1.5 mg TRPV4-GFP (as indicated in the text and figures). The shTRPV4 construct was made using the following sense (5 0 -CACCGATCTGCTGGAGTCCACCCTA CGAATAGGGTGGACTCCAGCAGATC-3 0 ) and antisense (5 0 -AAAAGATCTGCTGGAGTCCACCCTATTCGTAGGG TGGACTCCAGCAGATC-3 0 ) oligonucleotides. The corresponding control shRNA with a scrambled sequence was made using the sense (5 0 -GATCTTGGTCGTGCGCTCTTA-3 0 ) and antisense (5 0 -TAAGAGCGCACGACCAAGATC-3 0 ) oligonucleotides. To enable directional cloning, both sense and antisense oligonucleotides had four nucleotides overhangs at the 5 0 end. These two oligonucleotides were hybridized in equal molar ratio and cloned into pENTR/U6 vector. Sequence TRPV4-mediated tumor derived endothelial cell migration A Fiorio Pla et al identity of the cloned plasmids was then confirmed by sequencing. The shTRPV4 was used in TRPV4 silencing experiments, whereas the scrambled shRNA or empty shRNA vectors were used as negative controls. Cells were transfected with 3 mg of these shRNAs for 72 h. For TRPV4-GFP construct, the TRPV4 DNA sequence was cloned in pAcGFP1-N1 vector. The shTRPV4 and TRPV4-GFP constructs were first assessed in western blot and Ca 2 þ imaging experiments before being used in subsequent experiments (Supplementary Figure  S1) . Lysates of HEK293 cells expressing TRPV4-GFP showed the expected B100 KDa band and a lower B70 kDa band, which may correspond to endogenous TRPV4 (Supplementary Figure S1C) . For the experiments showed in Supplementary Figure S3 , BTEC were transfected with 1.5 mg of b-actinmCherry vector (a kind gift from Dr Yamada) as described above.
Protein extraction and western blot analysis BTEC, RTEC and GEC were grown in EBM containing 10% FCS, whereas HMVEC were grown in EBM-2-MV medium until cells were 80% confluent. Cells were then detached, suspended in ice-cold 1 Â phosphate-buffered saline containing the following protease inhibitors: 2 mg/ml aprotinin, 1 mM Na orthovanadate, 0.1 mM PMSF and 10 mM NaF. Cells were centrifuged for 15 min at 1000 g, and resuspended in a lysis buffer containing (in mM): 100 Tris-HCl (pH 8.0), 1 MgCl 2 , in the presence of protease inhibitors and frozen at À80 1C for at least 2 h before use. Cells were subjected to one freeze-thaw cycle in the lysis buffer mixed with 2 Â sucrose solution to give a final concentration of 250 mM sucrose, and then homogenized by passing through a syringe tip. Protein concentration was determined using the Quanti-iT protein assay (Invitrogen, Carlsbad, CA, USA) following manufacturer instructions.
Conditions for SDS-PAGE and western blotting were as described previously (Fiorio Pla et al., 2005) . Polyvinylidene fluoride membranes were blocked and incubated for 2 h with rabbit anti-TRPV4 antibody (1:200) and the mouse IgG2a anti-b-actin (Sigma, St Louis, MO, USA) antibodies. The membrane was then washed with 1 Â TBS containing 0.1% Tween 20 and incubated as required with the HRP-conjugated anti-mouse or anti-rabbit IgG antibodies (Amersham, Piscataway, NJ, USA). Electrochemiluminescence was conducted using the SuperSignal West Pico chemiluminescent substrate (Pierce, Rockford, IL, USA). The anti-TRPV4 antibody was raised against the peptide C-DGHQQGYAPKWRAEDAPL in rabbits (Loftstrand Labs, Gaithersburg, MD, USA). The resulting rabbit serum was then affinity purified to obtain the anti-TRPV4 antibody. Specificity of the anti-TRPV4 antibody was determined using the TRPV4 peptide and comparing its detection of TRPV4 with the two commercial TRPV4 antibodies (Chemicon (Billerica, MA, USA) and Alomone (Jerusalem, Israel) TRPV4 antibodies; Supplementary Figure S2) . To quantify the differences in protein expression, the ratio between TRPV4 and actin expression was evaluated. One-way analysis of variance was performed to analyze data sets. Post-hoc tests were used to determine statistically significant differences among the groups (Student-Newman-Keuls test).
Wound-healing assays
Cell motility was investigated in terms of cell migration into a wound introduced in a confluent monolayer. Cells were grown to confluence on 24-well culture plates coated with 1% gelatin. BTEC were serum-starved for 24 h in Dulbecco's modied Eagle's medium containing 2% FCS. A 'wound' was made under standard conditions by scraping the middle of the cell monolayer with a P10 pipette tip. Floating cells were removed by washing with 1 Â phosphate-buffered saline, and the fresh Dulbecco's modied Eagle's medium (DMEM, serum-free for experiments conducted on BTEC or containing 2% FCS for the experiments conducted on HMVEC-d), with or without stimuli, was added (as indicated in the text or figures). Cell division could not be detected, to any significant degree, during the course of the experiments. Experiments were performed using a Leica TCS SP2 AOBS (Leica, Wetzlar, Germany) confocal microscope with a Â 10 objective. Cells were kept at 37 1C and 5% CO 2 for the all experiments, and a light image was taken every 2 h using the Leica software. Subsequent image analysis was performed using the ImageJ software (NIH, Bethesda, MD, USA) to quantify the percentage of wound reduction over time. To compare the percentage of cell migration, nonparametric unpaired t-test (WilcoxonMann-Whitney) was used as a scoring method.
[Ca 2 þ ] i measurements BTEC and HMVEC-d were loaded with the acetoxymethyl ester form of fura-2 (2 mM fura-2 AM (Invitrogen), 45 min at 37 1C). Cells were seeded on gelatin-coated glass coverslips at a density of 5000 cells/cm 2 at 1-2 days before the experiments and starved in DMEM 5% FCS for at least 2 h before the experiments. Fluorescence measurements were made using a Polychrome V spectrofluorimeter (TILL Photonics, Munich BioRegio, Germany) attached to an Olympus Â 51 microscope (Olympus, Tokyo, Japan) and Metafluor Imaging System (Molecular Devices, Sunnyvale, CA USA) (Liu et al., 2006) . During experiments, cells were maintained in standard extracellular solution of the following composition: 145 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 10 mM N-(2-hydroxyethyl)-piperazine-N 0 -ethanesufonic acid (HEPES), 10 mM glucose (NaOH to pH 7.35). Cells were continuously bathed with a microperfusion system. Each fluorescence trace (340/380 nm ratio) is representative of the traces seen in 50 cells obtained from at least two experiments. Student's t-test was used to statistically evaluate the data. The IgorPro software (Wavematrix, Lake Oswego, OR, USA) was used to further analyze the fluorescence trace to evaluate and use the agonist-induced slope change as a quantitative criterion to distinguish a cell response to an agonist from the background noise. One-way analysis of variance was performed to analyze data sets. Post-hoc tests were used to determine statistically significant differences among the groups (Student-Newman-Keuls test).
Immunofluorescence and confocal microscopy For immunofluorescence, BTEC were transfected with TRPV4-GFP vector as described above. After 48 h, cells were fixed using 3% paraformaldehyde and permeabilized using cold methanol on dry ice. Staining of F-actin was achieved using the rhodamine-labeled phalloidin (Invitrogen). Images were collected using a Leica TCS SP2 AOBS confocal microscope and analyzed using ImageJ software. Control experiments were carried out without primary antibody. In each field, we chose the stress fiber focal plane and analyzed the field with a plot profile of the major cell axis. Quantifications of the plasma membrane localization of TRPV4 were carried out using the fluorescence signals within the first 5 mm from the top of the cell, and calculating the ratio between the 5 mm fluorescence value and the peak amplitude within the 5 mm. One-way analysis of variance was performed to analyze data sets. Post-hoc tests were used to determine statistically significant differences among the groups (Student-NewmanKeuls test). For the in vivo experiments (Supplementary Figure  S3) , BTEC were transfected with b-actin-mCherry vector. After 48 h, cells were perfused with standard extracellular TRPV4-mediated tumor derived endothelial cell migration A Fiorio Pla et al solution (described above) in the presence of 10 mM 4aPDD. Cells were kept at 37 1C and 5% CO 2 for the all experiments, and confocal images were acquired before and at 10 and 15 min after 4aPDD perfusion using the Leica software.
Cell surface biotinylation Cells were treated as required and incubated for 20 min with 1.5 mg/ml. Sulfo-NHS-LC-Biotin (Pierce) in 1 Â phosphatebuffered saline (pH 8.0) on ice (Singh et al., 2004) . Following biotin-labeling, cells were washed and harvested in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 1% Triton X-100, 2 mM EDTA, 1 mM dithiothreitol, pH 7.4) supplemented with protease inhibitors as described earlier. Biotinylated proteins were pulled down with NeutrAvidin-linked beads (Pierce) and detected by western blotting. Band intensities of surface proteins were obtained using Quantity One 4.6.5 1D-analysis software (Bio-Rad, Hercules, CA, USA).
Online supplementary material
Supplementary Figure S1 shows the shTRPV4 and TRPV4-GFP constructs controls assessed in western blot and Ca 2 þ -imaging experiments. Lysates of HEK293 cells expressing TRPV4-GFP showed the expected B90 KDa band and a lower B70 kDa band, which may correspond to endogenous TRPV4. As control, the anti-GFP antibody was also used to detect TRPV4-GFP, which shows up on the blot as the B90 kDa band (Supplementary Figure S1C) . In addition, lysate of BTEC cells transfected with shTRPV4 construct show the extent of TRPV4 knockdown, which was more than 50% after 72 h (Supplementary Figure S1D) . Specificity of the anti-TRPV4 antibody was determined using the TRPV4 peptide and comparing its detection of TRPV4 with the two commercial TRPV4 antibodies (Chemicon and Alomone TRPV4 antibodies; Supplementary Figure S2 ). Experiments shown in Supplementary Figure S3 show that TRPV4 activation does not promote any actin remodeling by itself. BTEC were transfected with 1.5 mg of b-actin-mCherry vector (a kind gift from Dr Yamada) and live cell imaging was performed.
